Compare Biogen Inc (BIIB) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Medtronic PLC — how do they compare? Biogen Inc trades at $192.5 (market cap $28.34B), while Medtronic PLC trades at $79.42 (market cap $101.51B). The key difference: Medtronic PLC is far larger — about 3.6× Biogen Inc's market cap, and Medtronic PLC pays a 3.63% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | MDT | |
|---|---|---|
Market Cap | $28.34B | $101.51B |
Sector | Health | Health |
52-Week High | $216.63 | $105.35 |
52-Week Low | $122.68 | $73.75 |
Enterprise Value | $30.62B | $120.25B |
Dividend Yield | — | 3.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Medtronic (MDT) trades at $83.57, down 0.36% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $97.50. The company reported strong revenue growth to $33.54B in 2025, with net income of $4.66B and a net margin of 13.2%. Recent acquisitions, such as Scientia Vascular (PRNewsWire, 2026-06-12), and consistent earnings beats highlight operational strength and strategic expansion in medical technology.
MDT presents a compelling investment case with a 3.5% dividend yield and undervalued metrics relative to growth, but faces risks from rising debt levels and margin pressures. Analyst sentiment is strongly bullish with 58% buy ratings, though investors should monitor execution on fiscal 2027 guidance and macroeconomic headwinds impacting healthcare spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
